Peeling Back The Layers: Exploring Taysha Gene Therapies Through Analyst Insights
Portfolio Pulse from Benzinga Insights
Analysts have mixed opinions on Taysha Gene Therapies (NASDAQ:TSHA), with recent ratings showing a shift in sentiment. The average 12-month price target has decreased by 5.43%, with a current average of $6.62. Financial performance indicators reveal challenges, including a -27.52% decline in revenue growth and a high debt-to-equity ratio of 1.13.
August 12, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Analysts have mixed opinions on Taysha Gene Therapies, with a recent decrease in the average 12-month price target by 5.43%. Financial performance shows a -27.52% decline in revenue growth and a high debt-to-equity ratio of 1.13.
The decrease in the average price target and negative financial indicators such as declining revenue growth and high debt-to-equity ratio suggest a bearish short-term outlook for TSHA.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100